- Home
- EMPD vs ATRA Comparison
EMPD vs ATRA Comparison
Compare EMPD & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMPD | ATRA |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 129.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EMPD | ATRA |
|---|---|---|
| Price | $4.55 | $18.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 626.9K | 75.8K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | $2,624,202.00 | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.20 |
| Revenue Growth | N/A | ★ 51.27 |
| 52 Week Low | $4.04 | $5.01 |
| 52 Week High | $80.80 | $18.95 |
Technical Indicators
Market Signals| Indicator | EMPD | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 63.35 |
| Support Level | $4.04 | $16.59 |
| Resistance Level | $4.60 | $18.30 |
| Average True Range (ATR) | 0.25 | 1.24 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 54.55 | 67.06 |
Price Performance
Historical ComparisonAbout EMPD Empery Digital Inc.
Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).